This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tirado-Conde, G. Articles by Miravitlles, M. Search for Related Content PubMed PubMed Citation Articles by Tirado-Conde, G. Articles by Miravitlles, M. Social Bookmarking                   What's this?

Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency

Servei de Pneumologia. Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain

Beatriz Lara

Servei de Pneumologia. Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain

Marc Miravitlles

Servei de Pneumologia. Institut Clínic del Tòrax, Ciber Respiratorio 0/06/0028, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain, marcm{at}clinic.ub.es

Alpha-1 antitrypsin deficiency (AAT) is a hereditary recessive autosomal disease caused by mutations in the AAT gene. This disease is characterized by abnormally low AAT concentrations in plasma, which, in its homozygote form, carries a high risk for the development of early pulmonary emphysema and liver damage. Since the end of the 1980s augmentation therapy with AAT from human plasma has been available for specific treatment of emphysema due to AAT deficiency. Intravenous augmentation therapy has been demonstrated to be safe and weekly infusions of AAT have resulted in plasma AAT concentrations above those considered protective for the lungs. However, life-long weekly infusions are not well accepted by patients, therefore pharmacokinetic studies have been performed to try to individualize the therapeutic regimen in order to obtain adequate trough serum AAT levels with prolonged intervals of administration. Therapeutic regimens administered every two weeks appear to be safe and result in adequate trough serum concentrations, but less-frequent administrations result in trough levels below the target. Alpha-1-antitrypsin deficiency is largely unrecognized and underdiagnosed. The foundation of national and international registries is a valid strategy to increase awareness about the disease and collect information about the natural history of this deficiency. Furthermore, the identification of a large number of patients will allow the development of new clinical trials aimed at finding better treatments for this infrequent condition.

Key Words: Alpha-1-antitrypsin deficiency • management • emphysema • augmentation therapy

Therapeutic Advances in Respiratory Disease, Vol. 2, No. 1, 13-21 (2008)
DOI: 10.1177/1753465807088159


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?